The Promise and Perils of Biotech in Personalised Healthcare. Can New Regulatory Pathways Protect the Vulnerable?

Giovanni De Grandis, Irina Brass, Arthur Petersen

References

Wilson, J. M. (2017). 2017 Was the Year We Have Been Waiting For. *Human Gene Therapy Clinical Development*, *28*(4), 165-166.

EMA (2017). Advanced Therapies in Europe. Presentation at the 6th EBE Annual Conference on ATMPs – 5 December 2017, London. https://www.ebe-biopharma.eu/wp-content/uploads/2017/12/2017-AHS-pesentation-6th-EBE-Annual-Regulatory-Conference-5-Dec-17.pdf

Kuehn, B. M. (2017). The promise and challenges of CAR-T gene therapy. *JAMA*, 318(22), 2167-2169.

Bach, P. B., Giralt, S. A., & Saltz, L. B. (2017). FDA Approval of Tisagenlecleucel: Promise and Complexities of a $475 000 Cancer Drug. *Jama*, 318(19), 1861-1862.

Maschke, K.J. , Gusmano, M. K., & Solomon, M. Z. (2017). Breakthrough Cancer Treatments Raise Difficult Questions, *Health Affairs* 36 (10), pp. 1698-1700.

FDA (2004). Innovation or Stagnation: Challenge and opportunity on the critical path to new medical products. http://wayback.archive-it.org/7993/20180125035500/https://www.fda.gov/downloads/ScienceResearch/SpecialTopics/CriticalPathInitiative/CriticalPathOpportunitiesReports/UCM113411.pdf

EMA (2010). Road Map to 2015: The European Medicines Agency's contribution to science, medicines and health. http://www.ema.europa.eu/docs/en_GB/document_library/Report/2011/01/WC500101373.pdf

New York Times Editorial Board (2018). Easier drug approval: At what price? *New York Times*, June 9. https://www.nytimes.com/2018/06/08/opinion/drug-approval-cutting-prices.html

Kim, C., & Prasad, V. (2016). Strength of Validation for surrogate end points used in the US Food and Drug Administration's approval of oncology drugs. *Mayo Clinic Proceedings* 91(6), 713-725.

Carpenter, D., Zucker, E. J., & Avorn, J. (2008). Drug-review deadlines and safety problems. *New England Journal of Medicine*, *358*(13), 1354-1361.

Honig, P. K., & Hirsch, G. (2016). Adaptive Biomedical Innovation. *Clinical Pharmacology & Therapeutics*, *100*(6), 574-578.

United States Government Accountability Office (2016). FDA expedites many applications, but data for postapproval oversight need improvement. Publicly Released: Jan 14, 2016. https://www.gao.gov/products/GAO-16-192